Elevation Oncology, Inc. (ELEV): Price and Financial Metrics
ELEV Price/Volume Stats
Current price | $0.67 | 52-week high | $5.83 |
Prev. close | $0.66 | 52-week low | $0.50 |
Day low | $0.64 | Volume | 1,243,200 |
Day high | $0.70 | Avg. volume | 3,442,013 |
50-day MA | $0.65 | Dividend yield | N/A |
200-day MA | $1.49 | Market Cap | 39.71M |
ELEV Stock Price Chart Interactive Chart >
Elevation Oncology, Inc. (ELEV) Company Bio
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
ELEV Price Returns
1-mo | -5.81% |
3-mo | 21.82% |
6-mo | -17.08% |
1-year | -77.29% |
3-year | -82.69% |
5-year | N/A |
YTD | 19.09% |
2024 | 4.77% |
2023 | -43.47% |
2022 | -84.22% |
2021 | N/A |
2020 | N/A |
Loading social stream, please wait...